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the assessments with an ASMR I, II or III. 70% (n = 49) of the remaining evaluations 
where ASMR IV or V. ConClusions: In the first six years mAbs were perceived as 
a disruptive innovation to a significant proportion of ASMRs between I and III as 
a reward for research and development efforts of the manufacturer. This research 
suggest that mAbs manufacturers no longer benefit from a ‘first mover’ advantage 
and may face higher scrutiny from the TC and greater price pressure from the 
French pricing committee.
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HealtH tecHnology assessments of medical devices: is HelP out 
tHere?
Green W., Wood H.
University of York, York, UK
objeCtives: Small-Medium Enterprises (SMEs) should assess the potential profit-
ability of new medical devices early in their development. This can be achieved 
via early-stage health technology assessments (HTAs). However, many SMEs 
will not have the skills necessary to undertake these HTAs, so tools and frame-
works that aid this process are likely to be beneficial. A systematic review of the 
literature was undertaken to identify resources that can facilitate early-stage 
HTAs. Methods: Electronic databases, such as MEDLINE and ECONLIT, were 
searched in February 2013. Papers were included if they met all of the five selec-
tion criteria used. Results: Of the 4729 papers identified, ten were included in 
the final analysis. Only one interactive tool, a decision analytic model which is 
operational via Microsoft Excel, was identified. Of the remaining nine articles, five 
were classified as frameworks. Of these five articles, the most comprehensive out-
lines a multi-criteria decision analysis (MCDA) value matrix. The final three articles 
included in the final analysis contained descriptive methods with information that 
was considered useful. ConClusions: The resources available to aid the undertak-
ing of early-stage HTAs is very limited. Ideally, an interactive spreadsheet tool that 
generates intuitive results would be available. However, the one identified tool is 
too inflexible and most users would struggle to find accurate data to populate it. 
Unfortunately, these issues are likely to be endemic to any interactive tool for early 
modelling. As such other guidance, including frameworks, may be more useful if 
they are comprehensive. Only the MCDA framework article contained methods that 
the authors of this article considered comprehensive, and the use of MCDA for early-
stage HTAs has its own issues. Therefore, there may be a place in the literature for 
more complete pieces of guidance to undertaking early-stage HTAs.
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tHe nice medical tecHnology evaluation Programme (mteP) – 
insigHts for manufacturers considering notification
McLeod C.1, Howells R.1, Harrison L.2
1Abacus International, Manchester, UK, 2Abacus International, Bicester, UK
objeCtives: The Medical Technologies Evaluation Programme (MTEP) was 
established to promote the uptake of innovative medical technologies through the 
publication of Medical Technology Guidance (MTG) by the National Institute for Health 
and Care Excellence (NICE) to the National Health Service (NHS) in the UK. The objec-
tive of this analysis is to report data on the MTEP, which are not currently collated 
on the NICE website, in order to provide insights to manufacturers on the process, 
outcomes and implementation of guidance. Methods: Information published on 
the NICE website was used to identify notified technologies, the proportion routed to 
the MTEP, and the subsequent NICE recommendations. Results: Between January 
2010 and December 2012, 102 technologies were notified to the MTEP. Of these noti-
fications, 21 technologies were routed to MTEP and 15 were routed to the diagnostics 
assessment programme (DAP), giving a routing rate of 20% and 15%, respectively. Of 
the 21 technologies routed to MTEP, 13 technologies have had guidance issued: 10 
(77%) had a positive recommendation and 3 (23%) were not recommended for use in 
the NHS. Whilst a positive recommendation for use is likely to encourage uptake, it is 
not guaranteed. Following a positive MTEP recommendation for CardioQ-oesophageal 
doppler monitor (ODM), the implementation levels were relatively low (31% increase 
in use). ConClusions: Many of the notified technologies are not selected at notifi-
cation stage. However, once selected and routed to MTEP, most technologies receive 
some form of positive recommendation. Evidence on implementation levels following 
a positive recommendation by the NICE MTEP indicates that the implementation of 
guidance by the NHS may not always be optimal. The new NICE Health Technology 
Adoption Programme should help to improve implementation levels in the future. 
To ensure optimal implementation, manufacturers should consider developing tools 
to support the uptake of technologies alongside a NICE positive recommendation.
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decision from smc, cadtH, and Pbac
Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
objeCtives: Often positive reimbursement decisions are only achieved after 
multiple submissions. Multiple submissions can delay patient access to neces-
sary therapies and be costly for the manufacturer. This study analyzes the number 
of submissions needed to gain a positive decision and determines the lag time 
between the first submission and the positive decision. Methods: The data cov-
ered three agencies: SMC, PBAC, and CADTH’s Common Drug Review. The reviews 
spanned 23 disease conditions and included 396 Health Technology Assessments 
(HTAs). Results: A positive decision was achieved after the first submission in 50% 
of the HTAs analyzed. At 1.57 submissions, PBAC had the highest average number of 
submissions needed to achieve a positive decision. PBAC’s average was statistically 
higher than that of both CADTH and SMC (p< 0.001). On average, CADTH and SMC 
needed 1.17 and 1.16 submissions, respectively, to obtain a positive decision. Also, 
for drugs that were resubmitted, it took on average 430, 924 and 1,189 days to gain a 
positive decision from SMC, CADTH, and PBAC. For CADTH and SMC, there appears 
to be a modest linear relationship between the number of resubmissions needed 
ies, as well as demonstrating homogeneity and consistency among studies. Regarding 
to the statistical analysis, Bucher’s method is the most commonly used and is recom-
mended by most HTA bodies for indirect comparisons. Nevertheless, some HTA bodies 
(e.g. HAS, SMC), EUnetHTA and ISPOR Task Force on Indirect Treatment Comparisons 
consider that even if some direct evidence is available it is appropriate to validate the 
results using MTCs. According to these institutions, Bucher’s method is not appropri-
ate for the analysis of complex networks, while Bayesian approach is a more com-
prehensive method that can include meta-regression and study-level covariates. The 
use of the non-appropriate methods can derive to biased results. ConClusions: 
Methodology used for NMA should include all available evidence. Due to the increas-
ing complexity of network patterns, Bayesian analysis better meets HTA needs than 
the Bucher’s method, and is also a stronger evidence-deriving tool.
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scandinavian drug reimbursement and coverage decisions: tHe role 
of Hta
Grepstad M.L.1, Kanavos P.2
1London School of Economics and Political Science, London, UK, 2London School of Economics and 
Political Science, London, UK
objeCtives: To examine and explain differences and similarities in coverage 
decisions for outpatient pharmaceuticals in Denmark, Norway and Sweden, and 
to provide a better understanding of the current and future role of HTA in these 
countries. Methods: A comparative analysis of all outpatient drug appraisals 
carried out between 2009 and 2012, including an analysis of divergent coverage 
decisions for outpatient drug-indication pairs appraised by all three countries was 
performed. Agreement levels between HTA agencies were measured using kappa 
scores. Primary data collection through consultation with decision makers and 
academics in the three countries was carried out to obtain insight on how coverage 
decisions are made and why reimbursement outcomes differ in the three coun-
tries. Results: A total of 19 outpatient drug-indication pairs appraised in each of 
the three countries were identified, of which six pairs (32%) had divergent coverage 
decisions. An uneven distribution of coverage decisions was observed, with the 
highest number of overlap in appraisals in Norway and Sweden (freemarginal kappa 
0.89). Similarities were found in the criteria for reimbursement and the reasoning for 
coverage decisions. Differences in the appraisal methods applied and the interpreta-
tion of the evidence considered may explain divergent decisions. ConClusions: 
The study suggests that Norway and Sweden employ similar methods for outpatient 
drug appraisals and have less divergent reimbursement outcomes, while health 
economic evaluation is less prominent in Danish outpatient drug appraisal, leading 
to a lower percentage of reimbursements with restrictions or criteria.
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tHe imPortance of safety asPects in tHe amnog Process in germany: 
is tHe g-ba assessment consistent witH tHat of tHe cHmP?
Kuphal L., Witt B., Volmer T.
SmartStep Consulting GmbH, Hamburg, Germany
objeCtives: To assess the role of safety aspects in the overall AMNOG benefit 
assessment in Germany. Special attention was given to two aspects: (1) Are adverse 
events (AE) used systematically to change the benefit assessment in any direction? 
(2) Are safety aspects considered in the assessment in accordance with the scien-
tific CHMP opinion? Methods: Twenty-six benefit assessments decided and pub-
lished by the Federal Joint Committee (G-BA) between Jan 1st 2011 and Jun 6th2013 
were analyzed regarding the extent of harm. For each drug the extent of harm 
included with the consecutive influence on the overall benefit rating including 
potential changes in the overall rating scores was determined. Additionally, the 
safety aspects considered in the G-BA decision were compared to the CHMP assess-
ments. Results: For 19 of 26 drugs (73.1%), a greater or less harm vs. the compara-
tor determined by the G-BA was considered. In 12 of these 19 substances (63.2%) the 
rating of the additional benefit drawn from efficacy results remained unaltered due 
to safety aspects. In 5 procedures (26.3%) the G-BA rated the additional benefit solely 
on the basis of less harm vs. the comparator. In 2 procedures (10.5%) the G-BA found 
a greater harm vs. the comparator which negatively impacted the overall rating. 
Statistically significant results of ‘overall incidence of AE’, ‘AE grade 3-4’, ‘serious AE’ 
and ‘AE leading to study withdrawal’ were always considered by the G-BA. In 8 cases 
(42.0%), the G-BA weighted safety aspects differently from the EMA in its overall 
rating process. ConClusions: The AE profile is of major importance in the AMNOG 
process. It changed in more than one third of the drug assessments (7 cases; 36.8%) 
the efficacy based benefit ratings. In 8 cases (42.0%) the G-BA assessment deviated 
from the conclusions considered by the EMA.
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are monoclonal antibodies still considered as innovative by tHe 
frencH HealtH care system? a retrosPective analysis 2000-2012
Conti C.C.1, Kostakis A.1, Furniss S.J.2
1GfK Bridgehead, London, UK, 2GfK Bridgehead, Melton Mowbray, UK
objeCtives: To understand the dynamics of the Transparency Committee (TC) 
assessments of monoclonal Antibodies (mAbs) through the improvement in ther-
apeutic benefit (known as “ASMR”) ratings from 2000 to 2012. ASMR ratings are 
divided into two main groups by the French health care system. ASMR I to III allow 
manufacturers to notify price to the pricing committee based on the innovative 
character of the product and on the improvement provided over standard of care. 
This allows pricing at the “European” level. ASMR IV and V are given to non-inno-
vative products adding at best minor improvement to standard of care. Methods: 
mAbs (excluding radiotherapeutics) online published reports from the TC from 2000 
to 2012, including new indications and reassessments, were analysed. The TC has 
evaluated a total of 26 mAbs, leading to 105 ASMR ratings during the period stud-
ied. Results: From 2000 to 2006, 83% (n = 29) of the TC evaluations of mAbs led 
to ASMR I, II or III and only 17% of the TC evaluation lead to ASMR IV or V (n = 6). 
During the following period, from 2006 to 2012, the TC granted only 30% (n = 21) of 
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comes to the choice of the method of analysis. Cases of disagreement between 
G-BA and IQWiG are rarer in this area. In the case of Belimumab, the manufacturer 
chose to demonstrate the additional benefit by showing the add-on effect of the 
agent on-top of the appropriate comparator and not against it. This resulted in 
diverging benefit assessment by IQWiG and G-BA. ConClusions: The analysis 
of the assessment for all new active agents shows disparities between the assess-
ments of all parties involved. The AMNOG legislation has been in place for about 
two years and still, there are uncertainties in the choice of patient-relevant end-
points, comparators and method of analysis in the German benefit assessment 
process. Discussion is necessary to resolve diverging expectations about required 
methods and following assessments.
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tHe imPact of cost effectiveness on reimbursement aPProvals in 
france: a comParison of france and tHe united Kingdom
Purchase J.L.1, Nijhuis T.2
1Quintiles, Reading, UK, 2Quintiles, Hoofddorp, The Netherlands
objeCtives: To estimate the potential impact of the new health economic assess-
ment requirement on innovative products that came into law in October 2012 in 
France, by comparing the outcomes of recent Health Technology Assessments 
(HTA) in France (HAS) and the UK (NICE, SMC, AWMSG, JCVI). The hypothesis is 
that reimbursed products that achieved a high benefit score in France may have 
been rejected if the health economic case had to be demonstrated, as is required in 
the UK. Methods: A search was conducted to identify all therapies evaluated by 
HAS which were given a significant, important or moderate therapeutic improve-
ment score (ASMR I, II or III) between January 2010-June 2013. We then identified 
the assessments of the same product in the UK and compared the outcome of the 
assessment and the role of the economic evidence that was submitted. Results: 
Thirty-six therapies rated an ASMR I-III by HAS were found. Out of these 36, 19 
products had not (yet) been evaluated in the UK. For the remaining 17 that had 
been assessed by both countries, only one was not recommended by at least one of 
the UK agencies. NICE’s primary reason for rejecting the said intervention was due 
to the ‘clinical and cost effectiveness’. Similarly the SMC stated the economic case 
of the drug had ‘not been demonstrated’, and the long term clinical effect remains 
unknown. ConClusions: Initially, it doesn’t appear that economic evaluations 
based on QALYs considerably influence the outcomes of HTAs. Only one assessment 
was rejected by both UK agencies based on economic grounds but was awarded an 
ASMR III. Since most products have been endorsed by the UK agencies, the French 
system’s incorporation of health economics will not necessarily be an additional 
hurdle that cannot be overcome.
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web-based of toPic selection for comParative effectiveness 
researcH in Korea
Kim H.S., Lee D.S., You J.H.
National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea
objeCtives: As the only health technology evaluation institution in Korea, National 
Evidence-based Healthcare Collaborating Agency has made efforts to establish the 
topic selection model of comparative effectiveness research which corresponds to 
Korean situations in order to revitalize it since 2012. Methods: As a result of pre-
paring thetopic selection process of the comparative effectiveness research accord-
ing to these efforts and of conducting model operations in 2012, solution to access 
to the proposal process of research topics and a close examination of research 
methodologies was proposed as improvement point. Results: Accordingly, web-
based research topic proposal systems(www.necacer.re.kr) were designed in order 
to solve access to the proposal process of research topics and to increase trans-
parency of the early stage of research in 2013. To make a close examination of 
the possibility of research performance in multidisciplinary fashion, evaluation 
systems of three stages were divided to operate but web-based design which is the 
same as topic proposal systems was done reflecting the evaluator’s geographical 
access etc. Concretely, web-systems for topic proposal are composed of writing 
proposed research topic, writing proposed content of a topic, and confirming and 
submitting stages after writing basic information after login, and evaluative web 
systems were composed as follows: Step 1 is composed of quantitative evalua-
tion based on 6 standards, step 2 qualitative evaluation based on 6 standards, and 
step 3 investigation process based on 4 standards in relation to research topics 
refined. ConClusions: It is conceived that Korean web-based topic selection sys-
tems of comparative effectiveness research prepared systematically taking Korean 
situation into consideration will be able to contribute to improving qualitative 
aspects of research and enhancing researchers’ credibility by transparent opening 
the whole process of proposing, selecting and confirming topics.
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relevance of indirect comParisons in tHe german early benefit 
assessment (amnog)
Lebioda A.1, Gasche D.1, Dippel F.W.2, Plantör S.1
1IMS Health GmbH & Co. OHG, Munich, Germany, 2Universität Leipzig, Leipzig, Germany
objeCtives: Early benefit assessment in Germany under the AMNOG legislation 
requires a direct comparison with the appropriate comparator determined by the 
Federal Joint Committee (G-BA). In case no head-to-head studies are available, sub-
mission of indirect comparisons is permitted to assess the additional benefit of the 
new drug. The aim of this study was to comprehensively analyze the submissions 
of indirect comparisons reviewed so far by the Institute for Quality and Efficiency 
in Health Care (IQWiG) from January 2011 until May 2013. Methods: A systematic 
review of all 48 published assessment reports was performed. Results: There is 
a mismatch between the original intention of the early benefit assessment and 
its actual outcome. Until May 2013, 14 indirect comparisons have been conducted 
and submitted by manufacturers regarding the early benefit assessment. Only one 
indirect comparison has been accepted in a subindication by the IQWiG. However 
to obtain a positive decision and the number of unique drugs reviewed within the 
disease condition (r= .46 and .41, respectively). This relationship was not observed 
for PBAC (r= 0.01). ConClusions: PBAC required a greater number of submissions 
to gain a positive decision and the lag time to a positive decision is longer compared 
to SMC and CADTH. The number of submissions needed to gain a positive decision 
by CADTH and SMC were similar, but CADTH’s lag time was double that of SMC. For 
both SMC and CADTH, the number of drugs reviewed in a disease condition was 
positively correlated with the number of times a drug had to be submitted in order 
to gain a positive decision.
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draft versus final guidance in nice’s drug tecHnology aPPraisal 
Process
McGee M.A.1, Izmirlieva M.2, Ando G.2
1IHS Global Insight, London, UK, 2IHS, London, UK
objeCtives: The study sought to establish the pattern by which draft versus final 
technology appraisal’s (TA) for drugs have been issued by UK’s NICE. In particular, 
the study focused on variations between the draft versus final guidance, and the 
rationale for any changed recommendations during the appraisal process. Methods: 
The current study is based on a review of NICE’s 13 draft guidance and subse-
quent final guidance issued over the time period from November 2010 to mid June 
2013. Results: NICE issued five recommendations, four rejections and four rec-
ommendations subject to restriction, on drugs for use within the NHS in England 
and Wales. Four out of the five final recommendations had been overturned from 
an initial non- recommendation, to gaining a positive decision in final guidance. 
Meanwhile, all four final rejections corresponded to the recommendations made in 
its respective draft guidance. With one exception, all recommended drugs had an 
ICER below GBP30,000. None of the drugs rejected in the final guidance had a Patient 
Access Scheme offered. ConClusions: One-third of the 13 decisions were positive 
recommendations, a trend that is significantly lower than the average between 1 
March 2000 to 31 May 2013, when 62% of TA’s gained a positive final recommendation. 
Aside from clinical issues, the overriding rationale for the rejections were attributed 
to the high ICERs, coupled with the lack of PAS. This is compared to the case of, for 
example, ipilimumab, where a PAS offered in the final guidance lowered the ICER 
from GBP54,000 - GBP70,000 per QALY gained to GBP42,200 and essentially overturned 
NICEs initial non-recommendation. As seen in half of the initial rejections, NICE has 
overturned several decisions in favour of the manufacturer prior to final guidance.
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accePtance of surrogate endPoints by Hta agencies in euroPe
Es-Skali I.J., Nijhuis T.
Quintiles, Hoofddorp, The Netherlands
objeCtives: To compare how different European HTA agencies assess surrogate 
endpoints to demonstrate efficacy. Methods: We identified 8 therapies with sur-
rogate endpoints that were evaluated in the last 6 years by NICE and/or SMC (UK), 
HAS (France) and G-BA (Germany). The acceptability of the use of surrogate end-
points and any specific comments made by these agencies were analysed. Results: 
Commonly used surrogate endpoints such as glycated haemoglobin (HbA1c) in 
diabetes, progression free survival (PFS) in oncology and forced expiratory volume 
(FEV1) for respiratory diseases have been generally accepted as sufficient evidence 
to gain reimbursement by HTA agencies. Especially when a surrogate endpoint 
has been accepted by EMA, it is usually considered a valid outcome measure. Less 
well-accepted were several surrogate cardiovascular endpoints such as 6 minute 
walk test, blood pressure and LDL cholesterol. For G-BA it is important that sur-
rogate endpoints have been properly validated and are patient relevant but they 
did accept endpoints such as sustained virological response (SVR) for hepatitis 
treatments, FEV1 and body mass index (BMI) based on minor evidence. NICE and 
SMC also strongly value evidence to demonstrate the correlation between surro-
gate endpoints and clinical outcomes. Interestingly SMC has recently become more 
cautious in accepting widely established endpoints such as HbA1c. With regards 
to the HAS, they often did not comment on the use of surrogate endpoints at all 
in their published reports. ConClusions: The use of surrogate endpoints in the 
assessment of clinical benefit is still controversial; however, attempts are made to 
establish clearer regulations such as the recently published EUnetHTA guidelines 
regarding surrogate endpoints. In the absence of evidence on final patient-relevant 
clinical endpoints, several commonly used biomarkers and intermediate endpoints 
will be considered as valid surrogate endpoints by HTA agencies. Newer, less estab-
lished surrogate endpoints will be more subject to strict validation requirements.
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a comParison of german benefit assessments by g-ba, iQwig and 
manufacturers
Eheberg D.1, Lebioda A.2, Hülsebeck M.2, Plantör S.2
1IMS Health, Munich, Germany, 2IMS Health GmbH & Co. OHG, Munich, Germany
objeCtives: In the German HTA process (AMNOG) the choice of the patient-
relevant endpoint, the appropriate comparator and the method of analysis are 
known to be decisive for the G-BA’s resolution of an additional benefit. Therefore, 
we aimed to analyze differences between manufacturer’s dossiers and G-BA / 
IQWiG assessments. Methods: The analysis will take into account all completed 
AMNOG assessment procedures. We analyzed all G-BA resolutions in compari-
son to IQWiG assessments and the manufacturer. Results: One major point of 
discrepancies occurred in the declaration of patient-relevant endpoints. By June 
2013, 58 surrogate endpoints were declared by IQWiG and manufacturers mainly 
in the indications oncology, infectious diseases and diabetes. The G-BA clearly 
states that only valid patient relevant endpoints are to be considered. However, 
there remains uncertainty around the term “patient-relevant” and which criteria 
have to be met for the IQWiG to accept an endpoint as patient-relevant. To date, 
54 comparisons were made in the dossiers to show an additional benefit of a new 
agent. The pharmaceutical manufacturer and the IQWiG often disagree when it 
